Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ENP.AU
- Price
- 0.03
- Stock movement up
- +- (0.00%)
- Company name
- Entropy Neurodynamics Limited
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Biotechnology
- Market cap
- -
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -20.93%
- 3 year return
- -66.11%
- 5 year return
- -43.20%
- 10 year return
- -
Last updated: 2025-12-11
DIVIDENDS
ENP.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.03 |
| Daily high | 0.03 |
| Daily low | 0.03 |
| Daily Volume | 750K |
| All-time high | 2.09 |
| 1y analyst estimate | - |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ENP.AU | S&P500 | |
| Current price drop from All-time high | -98.37% | - |
| Highest price drop | -99.19% | -19.00% |
| Date of highest drop | 2 Oct 2024 | 8 Apr 2025 |
| Avg drop from high | -66.82% | -2.65% |
| Avg time to new high | 117 days | 6 days |
| Max time to new high | 1008 days | 89 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Camberwell, Australia.
Employees
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found